In one paragraphArticle in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
10 authors.
Praveen Kumar GuttulaDepartment of Mechanical and Industrial Engineering, Louisiana State University, Baton Rouge, LA 70803, USA.ORCID 0000-0002-9612-8097 Ganesan MuthusamyDepartment of Veterinary Clinical Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA.
Chin-Chi LiuOffice of Research and Graduate Education, School of Veterinary Medicine, Louisiana State University, Baton Rouge, Louisiana 70803, USA.ORCID 0000-0003-0723-8313 Priscilla DevoraDepartment of Veterinary Clinical Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA.
Emi SasakiLouisiana Animal Disease Diagnostic Laboratory and Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, Louisiana, USA.ORCID 0000-0003-2192-7051 Tyler ButschDepartment of Pathobiology and Diagnostic Investigation, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan 48824, USA.
Hasand GandhiDepartment of Integrative Biology, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan 48824, USA.
James MoranDepartment of Integrative Biology, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan 48824, USA.ORCID 0000-0001-9081-9017 Manas Ranjan GartiaDepartment of Mechanical and Industrial Engineering, Louisiana State University, Baton Rouge, LA 70803, USA.ORCID 0000-0001-6243-6780 Andrea N JohnstonDepartment of Veterinary Clinical Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA.ORCID 0000-0003-1082-1155 Funding
Strategic inhibition of EGFR-family signaling using novel peptidomimetic inhibitors of HER-2 for the treatment of osteosarcomaP20GM135000 · NIGMS · LOUISIANA STATE UNIV A&M COL BATON ROUGE · PI CHAMCHEU, JEAN CHRISTOPHER · 2021 to 2025
$11.3MSpatial metabolomics with subcellular resolution to identify therapeutic targetsR35GM150564 · NIGMS · LOUISIANA STATE UNIV A&M COL BATON ROUGE · PI Manas Ranjan Gartia · 2023 to 2026
$1.5MNIGMS NIH HHS P20 GM135000NIGMS NIH HHS R35 GM150564
6 · The paper itselfAbstract
The mitochondrial membrane protein phosphoglycerate mutase 5 (PGAM5) is a protein of interest in the complex transition from hepatic steatosis to hepatocellular carcinoma. PGAM5 is a serine/threonine/histidine phosphatase that plays a role in mitochondrial biogenesis, mitophagy, and multiple cell death pathways. Increased expression of PGAM5 in hepatocellular carcinoma is correlated with reduced patient survival. In this study, we demonstrate that loss of PGAM5 alters the bioenergetic landscape of liver cancer by promoting mitochondrial oxidant injury and suppressing the glycerophospholipid and lysophospholipid pathways, leading to accumulation of the bioactive phospholipid lysophosphatidylcholine. Additionally,
Indexed as
Diacylglycerollysophosphatidylcholinemetabolic dysfunction-associated steatotic liver disease (MASLD)mitochondrial metabolismPGAM5sphingolipid
Identifiers
PMID42146432
PMCPMC13174629
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390